FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application

Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.